Policy: PAGB joins pharma and life sciences industries in joint statement on EU Exit

Published on: 28 November 2017

Joint statement from pharma, consumer healthcare and life science industries

PAGB has joined with associations in the UK and EU pharmaceutical, consumer healthcare and life science industry bodies, to issue a statement on EU Exit urging the UK and EU 27 to ensure a clear transition period and future cooperation agreements to safeguard access to medicines.

It calls for clarity and certainty as early as possible to enable our industry to make the necessary changes and to transition smoothly into the new framework.

Co-signatories to the statement include:  PAGB, Association of the British Pharmaceutical Industry (ABPI), The Association of the European Self-Medication Industry (AESGP); The European Federation of Pharmaceutical Industries and Associations (EFPIA); EUCOPE; EuropaBio; Medicines for Europe; British Generic Manufacturers Association (BGMA); and the BioIndustry Association (BIA).

PAGB’s participation reflects our view that the consumer healthcare industry faces many of the same challenges being articulated by our colleagues in the prescription pharmaceutical medicines, medical devices and food sectors. PAGB is working closely with colleagues in the trade associations for those industries and is supportive of issues raised by those sectors

PAGB supports the points made in the letter, which largely reflect PAGB’s EU Exit position